NIH begins Ebola vaccine trial
The Vaccine Research Center (VRC) at the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, has recently began its first human trial of a vaccine to prevent Ebola infection using the Biojector 2000 (B-2000) from Bioject Medical Technologies, a leading developer of needle-free drug delivery systems. The B-2000 is powered by a compressed gas system and is the only device being utilised in the study.
Earlier this year, Bioject entered into a services and supply subcontract with SAIC-Frederick, a subsidiary of Science Applications International Corporation-Frederick (SAIC-Frederick) under its contract with the National Cancer Institute, whereby Bioject will supply the VRC/NIAID, with the non-exclusive right to utilise Bioject's B-2000 needle-free injection systems in VRC-sponsored clinical trials for experimental vaccines against HIV and Ebola. The HIV human clinical trials are currently underway.